Results: Patients with SCCHN had significantly lower absolute numbers of CD3؉ CD4؉, and CD8؉ T cells than normal controls. However, no differences in the percentages of T-cell subsets between patients and normal controls were observed. Patients with active disease had significantly lower CD3؉ and CD4؉ T-cell counts than those with NED. Patients who had NED after surgery and radiotherapy had the lowest T-cell counts among the NED cohort. Patients who had NED for >2 years did not recover their T-cell counts, and the T-cell imbalance was evident many years after curative surgery. The tumor-node-metastasis (TNM) stage or site of the disease was not related to the absolute T-cell count. Patients with recurrent disease at the time of blood draw tended to have the lowest CD4؉ T-cell counts.
INTRODUCTION
Despite the constant input of new lymphocytes from the bone marrow and the thymus and the exponential generation of specific cells in response to antigens, the size of the peripheral lymphocyte pool remains relatively stable. To maintain homeostasis, the peripheral blood T-lymphocyte pool is regulated in complex ways that have not yet been fully defined (1) . In general, clonal expansions of specific cells are balanced by programmed cell death in other subpopulations and the maintenance of a relatively constant total peripheral blood T-lymphocyte count. We have reported previously that patients with squamous cell carcinoma of the head and neck (SCCHN) as well as melanoma and breast cancer have increased proportions of circulating T cells that bind annexin V and are, therefore, destined to apoptose (2) (3) (4) (5) . Due to this extensive apoptosis in the peripheral circulation and concomitant repopulation of the blood compartment with T cells from the immature cell pool, rapid turnover of effector cells takes place that is reminiscent of that described for patients with HIV (6, 7). These observations suggest that the evaluation of the proportions and absolute numbers of lymphocytes and their subsets in the peripheral circulation of cancer patients is important and might provide insights into redistribution of those lymphocyte subsets that mediate antitumor defense.
Patients with cancer who do not receive conventional therapies are not generally considered to be lymphopenic. Nevertheless, abnormalities in T-cell counts have been observed in patients with breast cancer, ovarian cancer, myeloma, head and neck cancer, or liver cancer (8 -11) . More importantly, some reports show associations of T-cell subset abnormalities with poor clinical outcomes (11) (12) (13) . However, there is no consensus on the extent of changes in different T-lymphocyte subsets in the course of cancer progression or its relationship with response to tumor-specific therapy or patient survival.
Absolute numbers of lymphocyte subsets in the peripheral circulation have been traditionally measured by dual-platform technologies, which couple percentages of positive cell subsets determined by flow cytometry with the absolute lymphocyte count obtained by automated hematology analyzers. Until recently, this was a standard, universally used technology, and it has been suggested that it is responsible for substantial differences in absolute lymphocyte counts reported by different laboratories (14, 15) . The more recent development of singleplatform technologies, which are performed entirely on the flow cytometer, has significantly improved the assay precision and accuracy and allowed for greater uniformity of results between laboratories (14 -16).
To evaluate a possible impact of spontaneous apoptosis of circulating T lymphocytes (2-5) on the peripheral T-cell pool, we investigated both the percentages and absolute numbers of CD3ϩ, CD4ϩ, and CD8ϩ T lymphocyte subsets in a large cohort of patients with SCCHN, using a single-platform flow cytometry-based method. We found that the presence of tumor as well as its recurrence had a significant impact on the absolute number of T-cell subsets. Both the type of therapy and length of the posttherapy period were considered, and the results suggested that regardless of these factors, lymphopenia was a persistent feature of the disease.
MATERIALS AND METHODS
Patients and Controls. In total, 146 patients with SC-CHN, who were seen consecutively between July 2001 and June 2003 at the Outpatient Otolaryngology Clinic at the University of Pittsburgh Oral Cancer Center, were entered into the study. The Institutional Review Board has approved the protocol for collection of patient blood samples. Normal healthy donors [normal controls (NCs)] were recruited among the laboratory personnel, family members of patients, and other volunteers, with an intent to match controls and patients for age. Subjects who served as NCs were interrogated for the general state of health, use of medications, smoking, and alcohol consumption. Written informed consent was obtained form each individual participating in this study.
The characteristics of all of the patients included in this study are shown in Table 1 . The cohort of 146 patients included 109 men and 37 women with a median age of 62 years (range, 24 -86 years), and the group of 54 volunteers comprised 25 males and 29 females with a median age of 54 years (range, 22-88 years). Of 146 patients, 48 had active disease, and 98 had no evidence of disease (NED) after surgery alone (n ϭ 56) or after surgery and radiotherapy (n ϭ 42; Table 1 ).
Collection of Blood Samples. Venous blood (10 ml) was obtained from the patients either the morning before surgery or during the outpatient visits and before any therapies. Blood samples were collected into heparinized tubes. Samples were also collected from age-matched NCs. Blood samples were hand-carried to the laboratory and immediately used for experiments.
Absolute Lymphocyte Count Determination. A standard single-platform technique, tetraONE System (Beckman Coulter, Miami, FL), based on four-color flow cytometry in the presence of counting beads was used. The identification of lymphocytes by expression of bright CD45 and low side scatter signals was followed by the identification of T-cell subsets based on the expression of CD3, CD4, and CD8, as described previously (16) . Briefly, 100 l of heparinized anticoagulated blood were incubated with 10 l of tetraCHROME reagent containing anti-CD45-FITC-, anti-CD4-RD1-, anti-CD8-ECD-, and anti-CD3-PE-Cy5 (Beckman Coulter)-labeled antibodies. Specimens were then lysed with the ImmunoPrep Reagent System at the Coulter TQ-Prep Workstation. Leukocyte morphology and cell surface integrity were maintained by a gentle, no-wash erythrocyte lysing method. Immediately before analysis, 100 l of Flow-count Fluorospheres (Beckman Coulter) were added to the stained cells, and the beads were counted along with cells. The sample acquisition and analysis were performed on the EPICS CL flow cytometer with a fully automated software-reagent combination. The number of cells (or cell subsets) per microliter was obtained by calculating the number of cells counted ϫ concentration of beads/number of beads counted. In each experiment, blood obtained from patients was evaluated together with blood from at least one NC. The one-platform method was validated in our laboratory by comparisons with the previously established two-platform method.
Statistical Analysis. Differences in percentages and counts of lymphocyte subsets between patients and NCs were age-adjusted by linear regression models after suitable data 
RESULTS

Analysis of T-Cell Subsets in Patients and
NCs. Using the single-platform method, we initially compared both the percentages and absolute numbers of CD3ϩ, CD4ϩ, and CD8ϩ cells in all patients with those in NCs. Because NCs were, on average, 8 years younger than patients, we first examined whether the percentages and counts of T lymphocytes changed with age to be able to correctly control for age differences when comparing patients with NCs. We found that the percentages of T lymphocytes were not associated with age ( Fig. 1) . However, the absolute counts of CD3ϩ and CD4ϩ but not CD8ϩ T cells decreased significantly with age in patients and NCs. As shown in Fig. 2 , the absolute counts for CD3ϩ cells decreased for patients and NCs with an estimated slope of Ϫ7.3 (P ϭ 0.02) between the ages of 24 and 88 years. CD4ϩ cells decreased with a slope of Ϫ5.5 (P ϭ 0.01). CD8ϩ T cells were unrelated to age in either group (P ϭ 0.66).
In comparing patients with NCs, no significant differences were observed in the percentages of T-cell subsets ( Fig. 1 ; Table  2 ). Age-dependent comparisons of absolute lymphocyte counts in patients versus NCs were adjusted for age. The patients had 382 fewer CD3ϩ cells, 297 fewer CD4ϩ cells, and 85 fewer CD8ϩ cells per mm 3 than NCs. These significant differences (P Ͻ 0.0001 for CD3ϩ and CD4ϩ cells; P Ͻ 0.03 for CD8ϩ cells) were detectable at any age (Fig. 2) . Overall, the patients had significantly lower absolute T-cell counts but not percentages than NCs, and the absolute numbers of CD8ϩ T cells were the least depressed in patients with SCCHN relative to NCs.
The CD4/CD8 Ratio in Patients and Controls. The mean CD4/CD8 ratio was not significantly different between Fig. 1 Percentages of CD3ϩ (A), CD4ϩ (B), and CD8ϩ (C) T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck and normal controls distributed according to age. The horizontal axes show a rug plot of case incidence by age (1 tick/subject). The top axis displays normal controls, and the bottom axis displays patients. Fig. 2 Absolute counts of CD3ϩ (A), CD4ϩ (B), and CD8ϩ (C) T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck and normal controls distributed according to age. As indicated by the regression lines, numbers of CD3ϩ and CD4ϩ T cells decreased with age in normal controls and patients with squamous cell carcinoma of the head and neck (P ϭ 0.02 and 0.01, respectively). However, the patients had significantly lower numbers of CD3ϩ, CD4ϩ, or CD8ϩ T cells than normal controls at any age (P Ͻ 0.0001 for CD3ϩ and CD4ϩ cells; P Ͻ 0.03 for CD8ϩ cells). The counts of CD8ϩ T cells were not related to age, and the horizontal lines in C depict the means for the number of CD8ϩ T cells in each cohort.
patients and NCs (P ϭ 0.21; Table 2 ). However, the same CD4/CD8 ratio does not discriminate between patients with a high versus low absolute count of the two lymphocyte subsets. In our series, for example, one patient with a CD4/CD8 ratio of 2.44 had an absolute count of 800 CD4ϩ cells and 328 CD8ϩ cells, whereas another patient with the same CD4/CD8 ratio of 2.44 had 155 CD4ϩ cells and 64 CD8ϩ cells. For this reason, we undertook a more detailed analysis of the relationship between the numbers of CD4ϩ and CD8ϩ T lymphocytes in individual patients, as shown in Fig. 3 . Relative to NCs, whose mean CD4/CD8 ratio is 2.4 ( Fig. 3A) , patients with active disease, whose mean CD4/CD8 ratio is 2.3, have decreased numbers of CD4ϩ and CD8ϩ T cells. As a result, there is a dramatic shift of the individual CD4/CD8 ratios to the bottom left quadrant in Fig. 3B . Not surprisingly, the patients with recurrent disease have the lowest absolute counts of CD4ϩ and CD8ϩ T cells (Fig. 3B) . Among the patients with active disease, a small subgroup (8 of 48 patients) with high numbers of CD4ϩ T cells and relatively normal counts of CD8ϩ T cells (top right quadrant in Fig. 3B ) is evident.
A somewhat different relationship emerges when CD4ϩ and CD8ϩ T cells are examined in the patients who, at the time of blood draws, had NED either after curative surgery or after surgery plus radiotherapy (Fig. 3C) . Here, it can be seen that patients previously treated with radiation therapy (RT) in addition to surgery had the lowest CD4ϩ counts. Other patients with NED had somewhat depressed CD4ϩ counts but normal CD8ϩ counts when compared with NCs (Fig. 3A) .
Effects of Postoperative Radiation or Chemotherapy on Absolute Lymphocyte Counts. Among 98 patients with NED at the time of blood draws, 42 had received postoperative RT. The postoperative RT consisted of 66 -70 Gy divided into 1.8 -2.0-Gy fractions over 35 individual daily fractions. This RT was applied within 6 weeks of surgery. No patient received hyperfractionated RT. The time duration between last RT and a blood draw for this study was variable, ranging from 1 to 302 months (mean Ϯ SD, 47 Ϯ 67 months). The patients who had RT also had significantly lower absolute numbers of CD4ϩ T cells (P Ͻ 0.0001) as well as CD3ϩ T cells (P ϭ 0.0043) compared with 56 patients with NED without prior RT (Fig. 4) . In contrast, the count of CD8ϩ T lymphocytes remained unchanged after RT, an indication that CD8ϩ T cells were not sensitive to RT. Nevertheless, it should be noted that 37 of 56 patients with NED treated with surgery alone also had comparably low CD4ϩ and CD8ϩ T-cell numbers, and, thus, RT was only one of the factors contributing to T-cell cytopenia in the patients.
Sixteen of 42 patients treated with surgery and radiotherapy also received chemotherapy, which was concluded at least 2 months before the blood draws for this study. The mean time period elapsed between last chemotherapy and the flow analysis was 18 Ϯ 27 months (range, 2-85 months). There was no difference in the CD4ϩ T cell (P ϭ 0.36) or CD8ϩ T cell (P ϭ 0.61) counts between patients receiving chemotherapy plus radiotherapy and patients treated with radiotherapy alone.
Effects of Surgery on Absolute Lymphocyte Counts. The cohort of 56 patients with NED who underwent curative surgery alone was divided into those treated Ͼ2 years before the blood draw and those studied within 2 years of surgery. As seen in Fig. 5 , the absolute numbers of the T-cell subsets were 3A ; P Ͻ 0.0001). The data suggest that effects of the tumor on the homeostasis of lymphocytes are observed long after the tumor is removed and in the absence of any other lymphoablative therapy.
In a small number of patients with active disease (n ϭ 7), we were able to obtain blood samples before and 2-4 months after curative surgery. It was interesting to note that the absolute count of CD4ϩ T cells decreased in four of seven patients after surgery, whereas that of CD8ϩ T cells recovered, coming up to the normal range in all patients except those with stage IV disease (data not shown).
Lymphocyte Counts and Disease. Among 42 patients with active disease at the time of blood draw before surgery, 30 were diagnosed as having primary tumors, and 12 were diagnosed as having recurrent or second primary tumors (Table 1) . CD4ϩ and CD8ϩ T-cell counts were significantly depressed in both these groups relative to NCs (Fig. 3B) . Although a trend toward lower CD4ϩ T-cell counts was noted for patients with recurrence or second primary tumors, this difference did not reach statistical significance (data not shown). In addition, there were six patients with recurrent disease after previous surgery, and these subjects had the lowest T-cell counts (data not shown). Similarly, among the patients who, at the time of blood draw, had NED after curative therapy (n ϭ 98), those treated for recurrence of a second primary tumor (n ϭ 19) had, on average, a 25% lower number of CD4ϩ T cells than the patients treated for primary disease (n ϭ 79), as shown in Fig. 6 (P Ͻ 0.06).
Neither disease stage, site, or nodal involvement defined for these patients at the time of curative surgery had any discernible effects on absolute lymphocyte counts determined at the time of blood draws (data not shown). It has to be stressed, however, that blood draws for lymphocyte counts were obtained at different time points relative to surgery and, in many cases, 4 or more years after curative therapy.
DISCUSSION
We sought to analyze both the percentages and absolute lymphocyte counts in a large cohort of SCCHN patients (n ϭ 146), 48 of whom had active disease, and 98 of whom had NED after having undergone curative therapy months or years before the blood draws obtained for this study. The rationale for the study was solely based on our earlier reports of significant levels of spontaneous apoptosis observed among circulating T lymphocytes in patients with SCCHN (2, 3) . This finding suggested that absolute lymphocyte counts might be depressed in these patients. Through the use of single-platform flow cytometry, it was possible to independently analyze the percentages and absolute numbers of the T-cell subsets in the patients' peripheral 5 Absolute counts of CD4ϩ and CD8ϩ T cells in individual patients with no evidence of disease (NED) after curative surgery. The patients studied at Ͻ2 years after surgery are represented by white squares, whereas those studied Ͼ2 years after surgery are represented by black squares. Note the low absolute counts of both CD4ϩ and CD8ϩ T cells in the patients with NED, regardless of the length of follow-up. No difference in the CD4ϩ/CD8ϩ ratio was observed between these two groups of patients with NED (P ϭ 0.56). The stippled lines represent mean values for CD4ϩ and CD8ϩ T-cell number in normal donors.
circulation. Interestingly, absolute numbers of CD3ϩ, CD4ϩ, and CD8ϩ T cells were found to be significantly decreased in the patient group, emphasizing the existence of a relative lymphopenia in the patients versus age-adjusted NCs, despite the apparently normal percentages of circulating T lymphocytes. Therefore, in this report, we emphasize the necessity of determining absolute counts, not percentages, of lymphocyte subsets in patients with cancer. The usually reported cell percentages are misleading because they do not consider total WBC count, which might be and frequently is altered in these patients, particularly after anticancer therapies.
The most interesting finding of this study, however, was the observation that the absolute count of CD8ϩ T cells, although significantly decreased in the patients versus NCs (and especially so in patients with active disease), appeared to recover and normalize in most patients with NED, whereas the CD4ϩ T-cell count did not. In view of the data reported by us previously, which had demonstrated preferential apoptosis of CD8ϩ T cells in the circulation of SCCHN patients with clinical characteristics similar to those of the patient cohort studied here (2, 3), we had expected to find significantly decreased numbers of circulating CD8ϩ T lymphocytes rather than CD4ϩ T lymphocytes in these patients. A possible explanation for this unexpected finding could be that the homeostatic mechanisms compensate for the selective apoptosis by a rapid expansion of CD8ϩ T cells in the periphery of patients with SCCHN. It is now known that lymphocyte numbers are not regulated through control of their production from stem cells but rather by survival and homeostatic proliferation of mature lymphocytes (17, 18) . Thus, if the number of lymphocytes is low, proliferation ensues and generates more cells. If the number of lymphocytes is high, excess lymphocytes die (17, 18) . This is exactly what we have observed in the circulation of patients with SCCHN, where expansion of CD8ϩ effector subsets (specifically, the CD8ϩCD45ROϪCD27Ϫ or CD8ϩCD28Ϫ subsets) was accompanied by their rapid demise by apoptosis (19, 20) . More recently, we have reported that the majority of CD3ϩCD8ϩtetramerϩ T cells detectable in the circulation of patients with head and neck cancer also bound annexin V (21) . Thus, the homeostasis of CD8ϩ T cells in the peripheral circulation of patients with head and neck cancer appears to be maintained by their rapid turnover, resulting in a relatively stable mean peripheral CD8ϩ cell count for the patient population as a whole. A situation associated with profound depression of the peripheral CD8ϩ T-cell count occurred in patients with stage IV disease, who failed to normalize CD8ϩ T-cell count after surgery. This observation suggests that in advanced disease, patients might fail to effectively compensate for the loss of effector cells.
Not surprisingly, the absolute counts of both CD8ϩ and CD4ϩ T cells were found to be highly variable in the patient cohort we studied. For CD8ϩ T cells, the range varied from Ͼ1500/mm 3 to Ͻ100/mm 3 . For CD4ϩ T cells, the range was Ͼ2000/mm 3 to Ͻ100/mm 3 . Patients with documented recurrence of disease or second primary tumor at the time of blood draw had the lowest T-cell counts of all studied. The observed trend was for CD8ϩ T cell counts to increase and for CD4ϩ T cell counts to decrease after tumor removal by surgery. However, one of the most interesting findings of this study was that SCCHN patients who had NED for 2 years or Ͼ2 years after curative surgery alone (no radiotherapy or chemotherapy) still showed an imbalance in the T-cell subsets. This imbalance was highly significant for CD4ϩ T cells, whereas CD8ϩ T cells tended to normalize. This observation suggests that the disease process has a profound and long-lasting impact on T lymphocyte homeostasis in patients with SCCHN. Others have suggested previously that lymphocyte counts have prognostic value in SCCHN (22) .
Another factor that had a significant impact on T-cell counts was the history of previous RT. Only CD4ϩ cells, but not CD8ϩ T cells, appeared to be affected by previous RT (Fig.  4) . Whereas this has been reported previously (e.g., Ref. 23) , the finding of decreased counts of CD4ϩ T cells long after the administration of RT was somewhat surprising. Apparently, CD4ϩ T cells are not only more sensitive to RT than CD8ϩ lymphocytes, but the restoration of the peripheral CD4ϩ T cell pool after RT is very slow. As indicated above, many patients with NED and no previous RT also had reduced CD4ϩ T-cell counts long after curative surgery. Thus, RT was not the only factor modulating the number of circulating CD4ϩ cells in a cohort of patients with SCCHN previously treated for their disease.
It has been reported recently that lymphocyte counts are predictive of survival in cancer (11) . Whereas the current study was not designed to address survival as end point, we considered the possibility that disturbed lymphocyte homeostasis might be especially prominent in patients with poor prognosis, i.e., stage IV disease and nodal metastases. However, we could not establish a statistically significant relationship between disease stage or its severity and lymphocyte counts based on retrospective data analysis. It should be noted that no predictive value for absolute lymphocyte counts or CD4/CD8 ratios for larynx preservation, response to therapy, or survival of patients with SC-CHN was seen in another study (24) .
The observed imbalance in T lymphocyte counts in a heterogeneous cohort of patients with SCCHN is likely to be mediated by several distinct mechanisms. In patients with NED, it could be due to a decreased thymic output of recent thymic emigrants, as reported by us previously (25) , leading to alterations in the size of naïve, memory, and effector pools. In patients with active primary or recurrent disease, it could be mediated by increased cell death (apoptosis) of CD8ϩ T lymphocytes in the peripheral circulation (2, 3). We are currently investigating each of these possibilities. Clearly, the snapshot in time represented by each patient's cell count, as reported here, does not reflect lymphocyte kinetics within the circulating lymphocyte pool. Dynamic techniques, taking advantage of novel methods of cellular labeling and serial measurements (6, 7) , are necessary to confirm that the T-cell turnover is altered in patients with cancer relative to NCs. The use of CD4/CD8 ratios without considering changes in absolute pool sizes can be misleading because changes in either the denominator or numerator might lead to the same ratio, as we have shown here.
Our results for patients with SCCHN are complementary to the findings of others who also report lymphocyte imbalance in cancer (10 -13) . Combined with the presence of functional abnormalities in T cells of patients with SCCHN, as reported by us previously (3, 5, 19, 20, 25) , the overall impression is that of decreased immune competence in these patients. Lowered T-cell numbers in the circulation could predispose the patients to infections, disease recurrence, or a second malignancy. It is, therefore, advisable to pay attention to T-cell counts during posttreatment visits, even when the patients have NED long after curative therapy. Our data emphasize that decreased T-cell counts reflect effects of the disease process on T-cell homeostasis and not just therapymediated alterations and that the imbalance is long-lasting. In view of the possibility that such persistent changes in homeostasis of T-cell subsets might adversely influence antitumor responses and promote recurrence, therapies designed to increase lymphocyte counts could be considered even in patients with NED.
